Corteva, Inc.

(New York Stock Exchange)
Back to all articles
Somewhat Bearish -35

Gear Up for Corteva, Inc. (CTVA) Q3 Earnings: Wall Street Estimates for Key Metrics

Analyst downgrade Earnings report AI-generated analysis

πŸ“‰ Analysts forecast Q3 earnings of $0.09 per share, marking a 139.1% year-over-year increase despite a projected revenue decline of 32.4% to $1.77 billion.

πŸ“Š Consensus EPS estimates have been revised downward by 7.4% in the last 30 days as analysts reassess initial projections for the quarter.

🌱 The Crop Protection segment is expected to drive growth with net sales reaching $1.79 billion, a 5% increase from the prior-year quarter.

🧬 Insecticides and biologicals within Crop Protection show robust projected growth of 11.1% and 7.5% respectively, offsetting declines in other categories.

🌾 The Seed segment faces headwinds with estimated net sales of $840.59 million, representing an 8.3% decrease from the year-ago quarter.

πŸ’° Operating EBITDA for Crop Protection is projected at $267.01 million, a slight decrease from $279.00 million in the same period last year.

πŸ“‰ CTVA shares have fallen 12.4% over the past month, significantly outperforming the S&P 500 composite which declined by only 5.4%.

πŸ”» The stock currently carries a Zacks Rank #5 (Strong Sell), indicating expectations for near-term underperformance relative to the overall market.

Bullish Signals
  • Corteva is projected to report quarterly earnings of $0.09 per share, reflecting a substantial 139.1% increase compared to the same period last year.
  • The Crop Protection segment is forecasted to achieve net sales of $1.79 billion, representing a positive 5% growth from the year-ago quarter.
  • Insecticides within the Crop Protection division are expected to surge by 11.1% year over year, reaching an estimated $454.34 million in net sales.
  • Biologicals sales are projected to grow by 7.5% to $157.96 million, while fungicides are anticipated to increase by 6.9% to $237.32 million.
Risk Factors
  • Total revenues are forecasted to decline significantly by 32.4% year-over-year to an estimated $1.77 billion for the upcoming quarter.
  • The Seed segment is expected to contract with net sales of $840.59 million, representing an 8.3% decrease from the prior-year quarter.
  • Analyst consensus estimates have been revised downward by 7.4% in the past 30 days, indicating a reassessment of initial growth expectations.
  • Operating EBITDA for Crop Protection is projected to decrease slightly to $267.01 million from $279.00 million in the year-ago quarter.
  • The stock has underperformed the broader market recently, dropping 12.4% over the past month compared to a -5.4% decline for the S&P 500 composite.
Full Analysis
Wall Street analysts predict Corteva, Inc. (CTVA) will report quarterly earnings of $0.09 per share for the upcoming Q3 report, representing a significant 139.1% increase compared to the same period last year. However, revenue forecasts indicate a challenging quarter with estimated net sales of $1.77 billion, reflecting a substantial year-over-year decrease of 32.4%. This divergence between earnings per share growth and revenue contraction highlights specific operational dynamics within the company's business segments. Analyst consensus estimates have recently undergone a downward revision of 7.4% over the past 30 days, signaling a reassessment of initial expectations by covering analysts. The breakdown of projected net sales reveals mixed performance across key divisions: Crop Protection is expected to grow by 5% to $1.79 billion, driven by strong growth in insecticides (+11.1%), biologicals (+7.5%), and fungicides (+6.9%). Conversely, the Seed segment faces a decline of 8.3%, estimated at $840.59 million. Despite the projected revenue drop, analysts forecast Operating EBITDA for Crop Protection to remain relatively stable at $267.01 million, down slightly from $279.00 million in the year-ago quarter. Recent stock performance reflects market caution, with CTVA shares declining 12.4% over the past month compared to a -5.4% decline for the S&P 500 composite. Consequently, the company currently holds a Zacks Rank #5 (Strong Sell), suggesting potential near-term underperformance relative to the broader market.